Is ivermectin-Azithromycin combination the next step for COVID-19?
Is ivermectin-Azithromycin combination the next step for COVID-19?
复制标题
DOI：
10.4103/bbrj.bbrj_109_20
复制
发表时间：
2020-08-01
影响因子：
1.4
通讯作者：
Lungnier, Claire
中科院分区：
文献类型：
--
作者：
Al-Kuraishy, Hayder Mutter;Hussien, Nawar Raad;Lungnier, Claire
针对新型冠状病毒感染疾病（COVID-19），对不同的实验药物和已批准药物进行了测试，以发现能减弱或阻止严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）发病机制的有效药物。在COVID-19中重新使用具有潜在致心律失常作用的旧批准药物（如氯喹）可能会增加因反致心律失常电位导致的心源性猝死的风险。美国食品和药物管理局（fda）批准了伊维菌素等可在48小时内杀死SARS-CoV-2的药物。阿奇霉素可以增强氯喹对COVID-19的抗病毒活性，因为它具有致病性和致死率高的潜在风险。阿奇霉素可延长QT间期，但伊维菌素与阿奇霉素间无明显相互作用，无扭转效应风险。因此，阿奇霉素-伊维菌素被认为是一种有效的联合治疗COVID-19的老年潜在心脏异常患者。
Different experimental and approved drugs were tested for coronavirus infection disease (COVID-19) to detect effective one that attenuates or prevents the pathogenesis of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). Repurposing of old approved drugs with the potential arrhythmogenic effect such as chloroquine in COVID-19 may increase the risk of sudden cardiac death due to torsadogenic potential. The Food and Drug Administration approved the drugs, such as ivermectin, which can kill SARS-CoV-2 within 48 h. Azithromycin augments the antiviral activity of chloroquine in COVID-19 with a high risk of morbidity and mortality through torsadogenic potential. There were no obvious interactions between ivermectin and azithromycin and without risk of torsadogenic effect despite the prolongation of QT by azithromycin. Therefore, azithromycin-ivermectin is regarded as an effectual combo for COVID-19 in elderly patients with underlying cardiac abnormalities.